Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHISTLE-PF trial of ENV-101 (taladegib) in idiopathic pulmonary fibrosis
2024-511754-41-00Phase 2Completed
- Sponsor
- Endeavor BioMedicines
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Taladegib with Placebo (2 arms). Primary endpoint: Change in percent predicted forced vital capacity from baseline to Week 24 compared with placebo. Started May 2025; status: completed.
02
Drugs
taladegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-511754-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511754-41-00.